Drug Trial Radar · NCT01820325
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Oct 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
6
Actual
Start
Sep 9, 2013
Primary completion
Jun 18, 2014
Study completion Jun 18, 2014
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 28, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Phase Ib part of the study aimed to determine the maximum tolerated dose/recommended Phase II dose (MTD/RP2D) of once daily buparlisib in combination with every-three-week carboplatin and paclitaxel in patients with previously untreated metastatic squamous NSCLC. The purpose of the Phase II portion of the study was to assess the treatment effect of adding buparlisib versus buparlisib-matching placebo to every-three-week carboplatin and paclitaxel on progression free survival (PFS) in patients with previously untreated metastatic squamous NSCLC.
Conditions
- Non-Small Cell Lunch Cancer
Interventions
BuparlisibDrug
Buparlisib placeboDrug
Placebo + Carboplatin + Paclitaxel
CarboplatinDrug
PaclitaxelDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD)Time frame: Cycle 1 (21 days)
- Progression Free Survival (PFS) as measured using RECIST 1.1Time frame: Randomization, every 6 weeks to the date of first document progression for up to 3 years
Locations
7 sites in 5 countries. Site status is shown where the registry gives one.
Highlands Oncology Group
Fayetteville, Arkansas
Northwest Cancer Specialists Compass Oncology -BKM
Portland, Oregon
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.